Actinium Pharmaceuticals publishes presentation on ATNM-400 antitumor activity in ovarian cancer models
ATNM•ATNM•ATNM•ATNM•Actinium Pharmaceuticals published preclinical ovarian cancer data showing ATNM-400 monotherapy achieved 93% tumor growth inhibition in an OVCAR-5 mouse model, versus 54% for bevacizumab. After bevacizumab failure, ATNM-400 achieved 50% inhibition and prolonged survival.
Actinium Pharmaceuticals published a presentation on ATNM-400 in preclinical ovarian cancer models. In an OVCAR-5 mouse model, ATNM-400 monotherapy achieved 93% tumor growth inhibition, compared with 54% for bevacizumab; combining the drugs achieved 85% inhibition, with no additional benefit over ATNM-400 alone. After bevacizumab failure, ATNM-400 achieved 50% inhibition and prolonged survival. Safety testing showed minimal blood, liver and kidney toxicity in mice, and ATNM-400-containing regimens prolonged survival in an immunocompetent ovarian cancer model.
